Market Cap 2.49B
Revenue (ttm) 7.00M
Net Income (ttm) -274.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,921.14%
Debt to Equity Ratio 0.00
Volume 864,100
Avg Vol 1,268,208
Day's Range N/A - N/A
Shares Out 87.64M
Stochastic %K 59%
Beta 0.14
Analysts Strong Sell
Price Target $47.59

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumor...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 443 6209
Address:
5000 Shoreline Court, Suite 300, South San Francisco, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 12:57 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IDYA Current Share Price: $29.18 Contracts: $IDYA April 17, 2026 $30 Calls Scale in: $5.51- $6.74 Scale out: $8.57-$11.03 Can Easily Capture: 60% ROI Blended DTE: 174 Days | Join Elites here: https://liquidtheta.com
0 · Reply
JackDarwin
JackDarwin Oct. 25 at 9:15 AM
$IDYA Above the Stomach Candlestick Pattern
0 · Reply
HolEKa1010
HolEKa1010 Oct. 24 at 3:22 PM
$IDYA okay I see the movement
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 10:38 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IDYA Current Share Price: $28.50 Contracts: $IDYA April 17, 2026 $30 Calls Scale in: $5.49- $6.71 Scale out: $8.54-$10.98 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 3:53 PM
JP Morgan has updated their rating for IDEAYA Biosciences ( $IDYA ) to Overweight with a price target of 79.
0 · Reply
Quantumup
Quantumup Oct. 23 at 11:30 AM
JPMorgan⬆️the PT on $IDYA to $79 from $74, reiterated at an Overweight, and⬆️ darovasertib's probability of success (PoS) in the neoadjuvant setting to 70% from 60%—estimates peak sales of $500M in the U.S. alone—sees share upside into the mUM update. $IMCR $PFE $MRK $BMY
0 · Reply
AVXLIMMINENTZERO
AVXLIMMINENTZERO Oct. 23 at 7:50 AM
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 1:12 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IDYA Current Share Price: $28.64 Contracts: $IDYA April 17, 2026 $30 Calls Scale in: $5.54- $6.77 Scale out: $8.61-$11.07 Can Easily Capture: 60% ROI Blended DTE: 177 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
CH_Expat
CH_Expat Oct. 22 at 6:56 PM
$IDYA Make of it what you want, but still the one bio I would still open a NEW position with most confidence.
0 · Reply
US_Bull
US_Bull Oct. 22 at 3:55 PM
$IDYA Started a position at 27,5$, 1,300 shares.
0 · Reply
Latest News on IDYA
Ideaya Biosciences: Moving Into ADCs For Solid Tumors

Aug 5, 2025, 8:43 AM EDT - 2 months ago

Ideaya Biosciences: Moving Into ADCs For Solid Tumors


Why Ideaya Biosciences Is Down Despite Many Positives

Apr 2, 2025, 11:12 AM EDT - 7 months ago

Why Ideaya Biosciences Is Down Despite Many Positives


LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 12:57 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IDYA Current Share Price: $29.18 Contracts: $IDYA April 17, 2026 $30 Calls Scale in: $5.51- $6.74 Scale out: $8.57-$11.03 Can Easily Capture: 60% ROI Blended DTE: 174 Days | Join Elites here: https://liquidtheta.com
0 · Reply
JackDarwin
JackDarwin Oct. 25 at 9:15 AM
$IDYA Above the Stomach Candlestick Pattern
0 · Reply
HolEKa1010
HolEKa1010 Oct. 24 at 3:22 PM
$IDYA okay I see the movement
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 10:38 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IDYA Current Share Price: $28.50 Contracts: $IDYA April 17, 2026 $30 Calls Scale in: $5.49- $6.71 Scale out: $8.54-$10.98 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 3:53 PM
JP Morgan has updated their rating for IDEAYA Biosciences ( $IDYA ) to Overweight with a price target of 79.
0 · Reply
Quantumup
Quantumup Oct. 23 at 11:30 AM
JPMorgan⬆️the PT on $IDYA to $79 from $74, reiterated at an Overweight, and⬆️ darovasertib's probability of success (PoS) in the neoadjuvant setting to 70% from 60%—estimates peak sales of $500M in the U.S. alone—sees share upside into the mUM update. $IMCR $PFE $MRK $BMY
0 · Reply
AVXLIMMINENTZERO
AVXLIMMINENTZERO Oct. 23 at 7:50 AM
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 1:12 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IDYA Current Share Price: $28.64 Contracts: $IDYA April 17, 2026 $30 Calls Scale in: $5.54- $6.77 Scale out: $8.61-$11.07 Can Easily Capture: 60% ROI Blended DTE: 177 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
CH_Expat
CH_Expat Oct. 22 at 6:56 PM
$IDYA Make of it what you want, but still the one bio I would still open a NEW position with most confidence.
0 · Reply
US_Bull
US_Bull Oct. 22 at 3:55 PM
$IDYA Started a position at 27,5$, 1,300 shares.
0 · Reply
CH_Expat
CH_Expat Oct. 21 at 7:51 PM
$IDYA Ah, soft bashing because these scammers want to increase their position.
1 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 6:02 PM
Goldman Sachs has updated their rating for IDEAYA Biosciences ( $IDYA ) to Neutral with a price target of 30.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Oct. 21 at 4:26 PM
$IDYA Massive volume decrease compared to recent days. Price currently at $29.86, with highest at $31.98 and lowest at $14.50. Recent price action shows a significant drop in volume from 1,737,000 to 521,014. Waiting for a lower H% before considering entry.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:08 PM
RBC Capital has adjusted their stance on IDEAYA Biosciences ( $IDYA ), setting the rating to Outperform with a target price of 38 → 41.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 21 at 10:23 AM
WATCHLIST OCT 21 2025 $LMT Lockheed Martin Says It Has Been Developing Moon Lander Plans That Could Fulfill Nasa's Need For Alternative To SpaceX's Starship $PCRX Pacira Biosciences To Present New Data From Phase 1 Clinical Trial Evaluating PCRX-201, Gene Therapy Candidate For Osteoarthritis Of Knee, At ACR Convergence 2025 Meeting $LPTH LightPath Technologies shares are trading higher after the company announced it received a $4.8 million purchase order for infrared camera systems. $IDYA BTIG Reiterates Buy on IDEAYA Biosciences, Maintains $62 Price Target $WD Walker & Dunlop Secures $40.5M Financing For 137-Unit Affordable Senior Housing Project "The Highlands" In Hyattsville, Maryland
0 · Reply
Quantumup
Quantumup Oct. 21 at 10:16 AM
RBC Capital⬆️the PT on $IDYA to $41 from $38 and reiterated at an Outperform after at ESMO IDYA presented data on eye and visual acuity preservation from daro in the neo-adjuvant setting, building on abstract data in the metastatic setting from Friday. $IMCR $PFE BMY RBC Capital added: Between the two datasets, we see evidence of very impressive anti-tumor efficacy leading to meaningful survival benefits, eye preservation and visual benefits, which we think increase the likelihood that upcoming ph.Ill trials will read out positively. While given the rarity of uveal melanoma, daro may be a somewhat smaller oncology opportunity, we think shares are not reflecting the combination of a ~$1B W.W. net revenue potential for daro and the pipeline assets IDYA has, and we are taking our tgt to $41 on the back of impressive UM data.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 10:11 AM
BTIG updates rating for IDEAYA Biosciences ( $IDYA ) to Buy, target set at 62.
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 20 at 4:56 PM
$IDYA Current Stock Price: $30.58 Contracts to trade: $30 IDYA Nov 21 2025 Call Entry: $1.50 Exit: $2.72 ROI: 82% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
notreload_ai
notreload_ai Oct. 20 at 12:44 PM
$IDYA shares rise after reporting breakthrough survival data for rare eye cancer treatment combining darovasertib with Pfizer's Xalkori in clinical trial. https://notreload.xyz/ideaya-biosciences-soars-eye-cancer-drug-results/
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 20 at 12:20 PM
$IDYA (+2.5% pre) IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress https://ooc.bz/l/81144
0 · Reply
US_Bull
US_Bull Oct. 20 at 10:48 AM
$IDYA This company is a gem just like BPMC it will get swooped up by BP both oncology precision medicine. Chart is also very bullish trying to get in.
1 · Reply
RonIsWrong
RonIsWrong Oct. 20 at 10:37 AM
$IDYA IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage 57% (24/42) eye preservation rate in enucleation (EN) recommended patients, which increased to 95% (19/20) in patients achieving ≥20% ocular tumor shrinkage 70% (26/37) of plaque brachytherapy (PB) eligible patients achieved a reduction in predicted radiation dose to the eye from baseline, resulting in 65% (24/37) of patients having lower predicted risk of vision loss 3-years post-PB treatment ~55% (29/53) of EN eligible and ~61% (23/38) of PB eligible patients demonstrated an improvement in baseline visual acuity scores (VAS) during neoadjuvant darovasertib treatment, with a mean gain of 17 and 10 letters, respectively Darovasertib has received U.S. FDA Breakthrough
1 · Reply